DK0781279T3 - Quinoxalindion-NMDA-receptorantagonister - Google Patents

Quinoxalindion-NMDA-receptorantagonister

Info

Publication number
DK0781279T3
DK0781279T3 DK95931989T DK95931989T DK0781279T3 DK 0781279 T3 DK0781279 T3 DK 0781279T3 DK 95931989 T DK95931989 T DK 95931989T DK 95931989 T DK95931989 T DK 95931989T DK 0781279 T3 DK0781279 T3 DK 0781279T3
Authority
DK
Denmark
Prior art keywords
pct
alkyl
group
date mar
ch2ch3
Prior art date
Application number
DK95931989T
Other languages
Danish (da)
English (en)
Inventor
Alan Stobie
Charles Eric Mowbray
David John Bull
Christopher Lee Carr
Michael Johnathan Fray
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Application granted granted Critical
Publication of DK0781279T3 publication Critical patent/DK0781279T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DK95931989T 1994-09-13 1995-09-01 Quinoxalindion-NMDA-receptorantagonister DK0781279T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9418443A GB9418443D0 (en) 1994-09-13 1994-09-13 Therapeutic agents
PCT/EP1995/003483 WO1996008485A1 (en) 1994-09-13 1995-09-01 Quinoxalinedione nmda receptor antagonists

Publications (1)

Publication Number Publication Date
DK0781279T3 true DK0781279T3 (da) 2001-09-03

Family

ID=10761258

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95931989T DK0781279T3 (da) 1994-09-13 1995-09-01 Quinoxalindion-NMDA-receptorantagonister

Country Status (14)

Country Link
US (1) US5783572A (de)
EP (1) EP0781279B1 (de)
JP (1) JP2898097B2 (de)
AT (1) ATE202099T1 (de)
CA (1) CA2199845C (de)
DE (1) DE69521323T2 (de)
DK (1) DK0781279T3 (de)
ES (1) ES2158126T3 (de)
FI (1) FI113471B (de)
GB (1) GB9418443D0 (de)
GR (1) GR3036270T3 (de)
MX (1) MX9701894A (de)
PT (1) PT781279E (de)
WO (1) WO1996008485A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110911A (en) * 1995-06-07 2000-08-29 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US5874426A (en) * 1995-06-07 1999-02-23 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
MY132385A (en) * 1995-08-31 2007-10-31 Novartis Ag 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
GB9605027D0 (en) 1996-03-09 1996-05-08 Pfizer Ltd Quinoxalinediones
AU5367598A (en) * 1996-11-25 1998-06-22 Warner-Lambert Company Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US6172065B1 (en) 1997-03-04 2001-01-09 Warner-Lambert Company Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US6340758B1 (en) * 1997-05-16 2002-01-22 Warner-Lambert Company Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents
TW526195B (en) 1997-06-10 2003-04-01 Novartis Ag Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and their use
DE19936521A1 (de) * 1999-08-06 2001-02-15 Gruenenthal Gmbh Substituierte Pyrrolidin-2,3,4-trion-3-oxim-Derivate
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー ユニバーシティ pHに依存するNMDAレセプターアンタゴニスト
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US20060142186A1 (en) * 2004-12-23 2006-06-29 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or NMDA receptor antagonists for the treatment of alzheimer's disease
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
EP2117540A1 (de) 2007-03-01 2009-11-18 Probiodrug AG Neue verwendung von glutaminyl-cyclase-hemmern
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
CN103058957A (zh) 2007-06-29 2013-04-24 埃莫里大学 用于神经保护的nmda受体拮抗剂
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
BR112013014484A2 (pt) * 2010-12-13 2016-07-19 Viamet Pharmaceuticals Inc compostos inibidores de metaloenzimas
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
DE102015011861B4 (de) 2015-09-10 2018-03-01 Rudolf Schindler Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
GB8827822D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
DK715888D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Quinoxalinforbindelser, deres fremstilling og anvendelse
DE4217952A1 (de) * 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
AU672617B2 (en) * 1992-06-22 1996-10-10 Regents Of The University Of California, The Glycine receptor antagonists and the use thereof

Also Published As

Publication number Publication date
GR3036270T3 (en) 2001-10-31
FI113471B (fi) 2004-04-30
EP0781279B1 (de) 2001-06-13
DE69521323D1 (de) 2001-07-19
GB9418443D0 (en) 1994-11-02
MX9701894A (es) 1997-06-28
ES2158126T3 (es) 2001-09-01
FI971026A0 (fi) 1997-03-12
DE69521323T2 (de) 2001-09-20
US5783572A (en) 1998-07-21
WO1996008485A1 (en) 1996-03-21
JPH09511523A (ja) 1997-11-18
CA2199845A1 (en) 1996-03-21
ATE202099T1 (de) 2001-06-15
EP0781279A1 (de) 1997-07-02
CA2199845C (en) 2000-08-01
JP2898097B2 (ja) 1999-05-31
PT781279E (pt) 2001-09-28
FI971026A (fi) 1997-03-12

Similar Documents

Publication Publication Date Title
DK0781279T3 (da) Quinoxalindion-NMDA-receptorantagonister
FI942187A (fi) Asyklisiä etyleenidiamiinijohdannaisia aine P-reseptoriantagonisteina
FI962753A (fi) Menetelmä lääkeaineena käytt¦kelpoisen piperidyyli- tai pyrrolidiinijohdannaisen tai sen farmaseuttisen suolan valmistamiseksi
DE69409525D1 (de) Acetamidderivate und ihre verwendung als modifizierungsmittel des verhaltens der verdauung
ES2114952T3 (es) Agentes antianginales derivados de quinazolinona.
NZ508910A (en) Di-substituted piperazine or piperidine derivatives useful as muscarinic antagonists
PT100620A (pt) Derivados de tetra-hidrocarbazol, seu uso e preparacao e composicoes farmaceuticas que os contem
DE69528485D1 (de) Biphenylderivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
GR3017648T3 (en) Use of (omega-(4-(2-pyrimidinyl)-1-piperazinyl)-alkyl)1H-azole derivatives for the preparation of medicines for the treatment of troubles of the capability of knowing functions.
DE69402981D1 (de) 3,5-dioxo-(2h,4h)-1,2,4-triazine als 5ht1a ligande
NZ331060A (en) Quinoxalinediones, preparation and pharmaceutical compositions thereof
NZ331613A (en) Piperazinyl or piperidinyl substituted 1,2,3,4-tetrahydronaphthalene derivatives
NZ333513A (en) 1,4-di-substituted piperidines and medicaments useful as muscarinic antagonists
DK0510003T3 (da) Piperidin-og pyrrolidinderivater
CA2374317A1 (en) Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators
ATE214056T1 (de) Benzodiazepinderivate
DK0553278T3 (da) 2-Phenyl- og 2-thienyl-(2)-piperidinderivater med neurobeskyttende egenskaber
DK0461012T3 (da) Derivater af ((1-arylpyrrolidin-2-yl)methyl)piperazin, fremstillingen heraf og deres terapeutiske anvendelse
MA26724A1 (fr) 1,2,3,4-tetrahydro-1-naphtalenamines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant